alexa Mucoviscidosis|omicsgroup|Journal Of Biotechnology And Biomaterials

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Mucoviscidosis

Lung transplantations associated risks such as acute and chronic graft rejection, the need for life-long immunosuppression and a five year survival rate of just above 50% lead to its classification as a treatment of last resort. In addition, the development of obstructive bronchiolitis over time is a major problem in these patients. Leading to transplantation early in life, Mucoviscidosis is the most frequent inborn cause of terminal chronic respiratory insufficiency with an incidence of 1 in 3000 live-births. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top